Aktienanalyse zu Puma Biotechnology Inc (PBYI)PBYIPuma Biotechnology Inc

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Puma Biotechnology Inc is currently trading at $9.83, which is above the analyst price target of $6, indicating that it may not be an attractive buy at this moment. The stock has a forward P/E ratio of 3.46, suggesting it is undervalued, but the RSI is at 42.73, indicating it is nearing oversold territory. The recent insider selling has increased by 230.93%, which raises concerns about future performance. Therefore, while the fundamentals show potential with a gross margin of 77.92%, the current market sentiment and insider activity suggest holding off on new purchases for now.

9 analysts cover PBYI: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 3.50.